What Does the Name CJC-1295 Mean?

CJC-1295 is a development name assigned to a specific synthetic growth hormone-releasing factor analog investigated by ConjuChem. The name functions as a compound identifier rather than a systematic description of the peptide sequence. The letters and numbers do not by themselves specify amino-acid length, receptor potency, molecular mass, experimental concentration, or pharmacokinetic behaviour. The molecular identity has to be established from the compound's published structure and analytical characterization.

This distinction supports the terminology framework in CJC-1295 Research. A recognizable development name is useful for finding literature, but it should not substitute for information about the modified GRF(1-29)-related backbone and albumin-binding structural component associated with the original CJC-1295 compound.

Research-use notice: InStrips products are offered for research and analytical use only. They are not intended to diagnose, treat, cure, or prevent any disease, injury, deficiency, absorption disorder, digestive condition, or medical condition.

CJC-1295 Is a Compound Identifier

Research and development programs commonly assign codes or project names to experimental compounds.

These identifiers allow researchers to track a molecule through:

• discovery studies
• analytical characterization
• animal research
• pharmacokinetic studies
• clinical development
• published literature

The code remains useful even when it does not reveal the complete chemical structure.

The Name Is Not a Chemical Formula

CJC-1295 should not be read as if each character encodes part of the molecular structure.

The name does not directly state:

• amino-acid sequence
• number of residues
• terminal modifications
• molecular formula
• molecular mass

Those properties require a molecular specification.

The Number 1295 Is Not Peptide Length

The number does not mean that the peptide contains 1,295 amino acids.

CJC-1295 is based on a much shorter GHRH-related peptide framework.

The Number Is Not Molecular Mass

The digits 1295 should not be interpreted as the molecular mass of the compound.

Molecular mass must be calculated or measured from:

• sequence
• amino-acid substitutions
• terminal groups
• additional conjugated structures

The Number Is Not an Experimental Amount

Development names sometimes contain digits that can be mistaken for dosing or concentration information.

CJC-1295 contains no embedded instruction about:

• experimental concentration
• sample amount
• frequency
• schedule

The Name Is Not a Receptor Code

CJC-1295 is the name of the research compound rather than the receptor it interacts with.

The relevant receptor is the growth hormone-releasing hormone receptor.

The Name Does Not Mean Native GHRH

A development code can identify an analog derived from an endogenous signalling system without being the name of the endogenous molecule itself.

CJC-1295 and native GHRH differ structurally.

The Name Does Not Mean GRF(1-29)

GRF(1-29) identifies a specific N-terminal portion of growth hormone-releasing factor.

CJC-1295 was developed from a modified GRF(1-29)-related backbone but contains substitutions and an additional structural extension.

The Name Does Not Mean Modified GRF (1-29)

Modified GRF (1-29) and CJC-1295 share a related tetrasubstituted peptide backbone in common terminology.

However, original CJC-1295 contains an additional albumin-binding C-terminal modification.

This molecular distinction makes the names non-equivalent.

Why Development Names Persist

A concise compound name makes it easier to:

• index publications
• compare experiments
• track development history
• reference a defined investigational material

The convenience of the name does not reduce the need for structural characterization.

ConjuChem Is Part of the Development History

CJC-1295 was developed within research associated with ConjuChem.

The compound name is tied historically to that development program.

This history can help distinguish the original research compound from later commercial uses of similar terminology.

Development History and Molecular Identity Are Different

Knowing where a compound was developed answers a historical question.

Knowing what the compound is requires molecular information.

A complete research description may therefore include both:

• development designation
• sequence and structural specification

The Underlying Backbone Is GHRH Related

CJC-1295 was designed around the active N-terminal region of human growth hormone-releasing factor.

This places it within GHRH analog research.

However, the relationship does not make the compound identical to endogenous GHRH.

Why the First 29 Residues Matter

Classic GHRH research established that the N-terminal region contains the principal sequence information associated with receptor activation.

This led to development of shorter GRF(1-29)-related analogs.

CJC-1295 belongs to this design lineage.

Modified GRF Backbone Terminology

The peptide framework associated with CJC-1295 includes multiple residue substitutions relative to native hGRF(1-29).

This modified backbone has also become important in the terminology surrounding Modified GRF (1-29).

The additional CJC-1295 albumin-binding structure must therefore be identified separately.

Tetrasubstituted Means Four Residues Are Changed

Tetrasubstituted is a structural term.

It means that four positions in the underlying peptide sequence differ from the corresponding residues in the reference GRF sequence.

It does not mean four peptide molecules are combined.

Substitutions Are Part of the Molecular Identity

A substituted peptide is chemically distinct from its parent sequence.

Researchers may evaluate substitutions in relation to:

• protease stability
• chemical stability
• receptor activity
• analytical properties

CJC-1295 Includes More Than the Tetrasubstituted Backbone

This is one of the most important naming points.

In the original molecular-design literature, CJC-1295 also contains a C-terminal lysine derivative with a maleimide-related group.

That additional feature is central to albumin bioconjugation.

What Does the Maleimide Group Do in the Research Design?

Maleimide chemistry can react with suitable thiol groups.

Researchers used this property to create an albumin-binding peptide design.

The maleimide group therefore forms part of the chemical architecture of the CJC-1295 research compound.

Albumin Binding Is Not Encoded in the Name Itself

Nothing in the characters CJC-1295 tells a reader directly that the compound contains an albumin-binding reactive group.

That information comes from the original structural literature.

This Is Why Names Need Definitions

A development name is useful only when the research community agrees on what molecular material it identifies.

A definition should ideally contain:

• reference sequence
• substitutions
• terminal modifications
• conjugated groups
• molecular mass

“CJC-1295 With DAC” Developed as Clarifying Terminology

Later commercial and secondary literature often adds “with DAC” to distinguish the albumin-binding form from materials called “CJC-1295 without DAC.”

From a historical molecular perspective, however, the original CJC-1295 compound already included the albumin-binding design.

DAC Is Not the Original Complete Compound Name

The peer-reviewed discovery literature generally refers to the compound as CJC-1295.

The additional wording “with DAC” is commonly used later as a clarification because non-DAC terminology became widespread.

Why “Without DAC” Creates a Naming Problem

If the albumin-binding structural feature is removed, the resulting peptide is no longer structurally identical to the compound originally identified as CJC-1295.

This is why rigorous research terminology often prefers Modified GRF (1-29) for the related non-DAC backbone.

Product Naming Can Drift From Research Naming

Commercial terminology can evolve independently of the original publication history.

A product catalogue may use:

• CJC-1295
• CJC-1295 DAC
• CJC-1295 with DAC
• CJC-1295 no DAC
• Modified GRF (1-29)

These labels should not be assumed to represent the same molecule.

A Label Should Be Resolved to a Molecular Structure

When one of these names appears, researchers should look for:

• complete amino-acid sequence
• C-terminal extension
• maleimide-containing modification
• molecular mass
• analytical confirmation

This provides stronger identification than the commercial name alone.

Why Molecular Mass Is Useful

Adding or removing the C-terminal albumin-binding structural component changes molecular mass.

Mass analysis can therefore help distinguish:

• CJC-1295
• Modified GRF (1-29)
• truncated materials
• other related analogs

Mass Spectrometry Can Add Identity Evidence

Mass spectrometry can evaluate:

• precursor molecular mass
• fragment ions
• sequence-associated fragments
• chemical modifications

This is more informative than relying on a short development name.

Chromatographic Purity Is a Separate Question

A sample can produce one major chromatographic peak without the peak necessarily having the expected CJC-1295 molecular identity.

Purity and identity therefore should remain separate analytical attributes.

Receptor Activity Is Also Not an Identity Test

A GHRH-related peptide may activate the GHRH receptor.

That response alone cannot distinguish necessarily among:

• native GHRH
• GRF(1-29)
• Modified GRF (1-29)
• CJC-1295
• another GHRH analog

Molecular characterization is required.

Biological Similarity Does Not Make Names Interchangeable

Two molecules can interact with the same receptor while remaining chemically distinct.

Research terminology should follow molecular structure rather than shared biological activity alone.

Why CJC-1295 Literature Searches Require Precision

A search for CJC-1295 may retrieve:

• original DAC-associated CJC-1295 research
• secondary discussions of Modified GRF (1-29)
• commercial no-DAC pages
• anti-doping analytical literature

The experimental molecule should be confirmed before evidence is grouped together.

Early Papers Provide the Strongest Naming Anchor

The earliest molecular-design papers describe what the development team called CJC-1295.

These sources are particularly valuable when later terminology becomes inconsistent.

Research Findings Should Follow the Defined Compound

If a study used albumin-binding CJC-1295, the findings should remain attached to that molecule.

If a study used Modified GRF (1-29), those findings should not be relabelled automatically as CJC-1295 research.

CJC-1295 Does Not Mean “Growth Hormone”

CJC-1295 is a GHRH-related analog rather than growth hormone itself.

The investigational peptide and downstream growth hormone are distinct molecular substances.

CJC-1295 Does Not Mean IGF-I

IGF-I is another distinct molecule measured downstream in some endocrine research.

A study may measure CJC-1295, GH, and IGF-I within the same protocol, but those measurements should remain separately identified.

The Development Name Does Not Describe an Outcome

CJC-1295 identifies the compound.

It does not establish:

• effectiveness
• benefit
• safety
• a clinical result
• a recommended use

The Development Name Does Not Provide a Protocol

Nothing about the name specifies:

• experimental amount
• route
• frequency
• duration

These are separate study-design variables.

Relationship to GHRH Terminology

CJC-1295 belongs to GHRH analog research but should not be used as another name for endogenous GHRH.

The molecular and terminology distinction is examined in CJC-1295 vs GHRH: Why the Terms Are Not Interchangeable.

Reading the Original Identification Paper

The PubMed-indexed paper Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog describes the structural modifications that led the investigators to identify one candidate as CJC-1295.

The paper provides a primary-source anchor for what the development name referred to molecularly. Its experimental findings should not be extended into claims about personal use, effectiveness, safety, or separately labelled research materials.

Final Perspective

CJC-1295 is a development name for a specific synthetic GHRH-related peptide analog rather than a systematic chemical description.

The name itself does not reveal peptide length, substitutions, molecular mass, albumin-binding chemistry, receptor potency, or experimental protocol. Those characteristics come from molecular and analytical research.

Accurate terminology should therefore connect the name CJC-1295 to the compound defined in the original literature and should distinguish it from native GHRH, GRF(1-29), Modified GRF (1-29), and later “without DAC” commercial naming conventions.